Plana N - Search Results

1

PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk.

Rehues P, Girona J, Guardiola M, Plana N, Scicali R, Piro S, Muñiz-Grijalvo O, Díaz-Díaz JL, Recasens L, Pinyol M, Rosales R, Esteban Y, Amigó N, Masana L, Ibarretxe D, Ribalta J. Rehues P, et al. Among authors: plana n. Int J Mol Sci. 2023 Jan 24;24(3):2319. doi: 10.3390/ijms24032319. Int J Mol Sci. 2023. PMID: 36768645 Free PMC article.

2

Effectiveness of probucol in reducing plasma low-density lipoprotein cholesterol oxidation in hypercholesterolemia.

Masana L, Bargalló MT, Plana N, LaVille A, Casals I, Solà R. Masana L, et al. Among authors: plana n. Am J Cardiol. 1991 Oct 1;68(9):863-7. doi: 10.1016/0002-9149(91)90400-f. Am J Cardiol. 1991. PMID: 1927944

3

[Familial combined hyperlipidemia: detection and characterisation of the hyperlipidemic profile among children and adolescents].

Ribalta J, La Ville AE, Heras M, Plana N, Masana L. Ribalta J, et al. Among authors: plana n. Med Clin (Barc). 1997 Jun 28;109(5):161-4. Med Clin (Barc). 1997. PMID: 9289537 Spanish.

4

Physicochemical changes in HDL3 after bezafibrate treatment: influence on free cholesterol efflux from human fibroblasts.

La Ville AE, Solà R, Motta C, Plana N, Heras M, Ribalta J, Masana L. La Ville AE, et al. Among authors: plana n. Cardiovasc Drugs Ther. 1997 Nov;11(5):653-8. doi: 10.1023/a:1007734924101. Cardiovasc Drugs Ther. 1997. PMID: 9493704

5

Simvastatin decreases aldehyde production derived from lipoprotein oxidation.

Girona J, La Ville AE, Solà R, Plana N, Masana L. Girona J, et al. Among authors: plana n. Am J Cardiol. 1999 Mar 15;83(6):846-51. doi: 10.1016/s0002-9149(98)01071-6. Am J Cardiol. 1999. PMID: 10190397

6

Treatment of type IIb familial combined hyperlipidemia with the combination pravastatin-piperazine sultosilate.

Masana L, Villoria J, Sust M, Ros E, Plana N, Pérez-Jiménez F, Franco M, Oliván JJ, Pintó X, Videla S. Masana L, et al. Among authors: plana n. Eur J Pharmacol. 2004 Aug 2;496(1-3):205-12. doi: 10.1016/j.ejphar.2004.05.041. Eur J Pharmacol. 2004. PMID: 15288592 Clinical Trial.

7

[Objective-oriented planification in the treatment of hypercholesterolemia].

Masana L, Plana N. Masana L, et al. Among authors: plana n. Med Clin (Barc). 2005 Jan 29;124(3):108-10. doi: 10.1157/13070853. Med Clin (Barc). 2005. PMID: 15710098 Spanish. No abstract available.

8

Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients.

Cabré A, Lázaro I, Girona J, Manzanares JM, Marimón F, Plana N, Heras M, Masana L. Cabré A, et al. Among authors: plana n. Atherosclerosis. 2007 Nov;195(1):e150-8. doi: 10.1016/j.atherosclerosis.2007.04.045. Epub 2007 Jun 5. Atherosclerosis. 2007. PMID: 17553506

9

Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes.

Cabré A, Lázaro I, Girona J, Manzanares J, Marimón F, Plana N, Heras M, Masana L. Cabré A, et al. Among authors: plana n. J Intern Med. 2007 Oct;262(4):496-503. doi: 10.1111/j.1365-2796.2007.01849.x. J Intern Med. 2007. PMID: 17875187 Free article.

10

Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria.

Cabré A, Lázaro I, Girona J, Manzanares JM, Marimón F, Plana N, Heras M, Masana L. Cabré A, et al. Among authors: plana n. Clin Chem. 2008 Jan;54(1):181-7. doi: 10.1373/clinchem.2007.094672. Epub 2007 Nov 16. Clin Chem. 2008. PMID: 18024526

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

195 results

Search Page

Filters